Skip to main content
Omvoh logo
  • Prescribing Information
  • Medication Guide
  • Instructions for Use
  • Enrollment Form
Menu closed
Omvoh logo
  • Prescribing Information
  • Medication Guide
  • Instructions for Use
  • Enrollment Form
Globe Loading... Reveal available languages
  • House For Healthcare Providers
    • How Omvoh Works
      • Omvoh for Ulcerative Colitis
      • Who Omvoh Is For
      • Clinical Data
      • Omvoh for Crohn’s Disease
      • Who Omvoh Is For
      • Clinical Data
    • Safety Profile
    • Dosing
    • Support for Your Patients
      • Lilly Support Services
      • Billing & Coding
      • Prescribing in EHR
      • Savings Program
    • Learn More About Omvoh from the Experts
    • Resources
  • For Consumers
Ask Lilly

We're here to help.

Phone Call:
1-800-LillyRx
(1-800-545-5979)
Link Visit Lilly Medical (HCP)
Question Sales Inquiry
Question Submit a Question
Chat Click to chat
Expand contact lilly
This site is intended only for U.S. Healthcare Providers

Support for your patients

Enroll Now
Resources
Billing & Coding
Prescribing in EHR
Savings Program

Lilly Support Services for Omvoh®

0:00-0:01
[background music]

0:02-0:06
[background music]

0:07-0:15
Narrator:
Lilly Support Services provides support options tailored to your patient’s entire treatment journey,...

0:16-0:24
Narrator:
...such as navigating coverage determinations,

0:25-0:34
Narrator:
...reimbursement challenges,

0:35-0:41
Narrator:
and proactive injection training for your patients.

0:25-0:34
Narrator:
...reimbursement challenges,

0:42-1:02
Narrator:
The Omvoh Savings Card Program provides support for infusion administration costs, intravenous infusions, and subcutaneous injections to make treatment more affordable for your eligible, commercially insured patients. Governmental beneficiaries excluded, terms and conditions apply.

1:03-1:13
Narrator:
Lilly Support Services offers 3 ways to enroll via the Lilly Support Services Provider Portal, CoverMyMeds®, and Fax enrollment.

1:14-1:37
Narrator:
The Lilly Support Services Provider portal offers an improved experience to help your patients get started on treatment quickly.

Key features of the provider portal include streamlined registration, seamless digital enrollment, an intuitive dashboard, real-time patient management, and customized support for your patients and office staff.

1:38-1:42
Narrator:
Enroll in Lilly Support Services now to get your patients started on Omvoh.

1:43-1:45
[background music]

1:46-1:49
[background music fades]

Empower your patients to start on Omvoh with Lilly Support Services.

Lilly Support Services is a customer support program with a suite of personalized services to help your patients start treatment quickly.

Access Support

  • Hospital icon

    Benefits Investigation

  • Hospital icon

    Prior authorization and appeals support

Procurement and Reimbursement

  • Hospital icon

    Coding and billing information

  • Hospital icon

    Identification of in-network infusion site or specialty pharmacy requirements

Patient Support

  • Hospital icon

    Savings programa,b

  • Hospital icon

    Injection Training and Patient Resources

  • Hospital icon

    Sharps disposal support

Your Field Reimbursement Manager (FRM) is your dedicated point of contact for all things related to access and reimbursement. To request support from an FRM contact your Lilly representative or call 1-800-LillyRx (1-800-545-5979).

Person icon

aThe Omvoh Savings Program is for eligible, commercially insured patients. The Omvoh Savings Program is not a guarantee of coverage.

bGovernmental beneficiaries excluded; terms and conditions apply.

Lilly Support Services Offers 3 Ways to Enroll:

Hospital icon

Lilly Support Services Provider Portal

A streamlined, easy-to-use digital enrollment process

Hospital icon

Fax Enrollment Form to 1-844-466-0006

Lilly Support Services or your FRM will reach out for any missing information

Hospital icon

Electronic prior authorization & digital enrollment services

aThe Omvoh Savings Program is for eligible, commercially insured patients. The Omvoh Savings Program is not a guarantee of coverage.

bGovernmental beneficiaries excluded; terms and conditions apply.

Billing and Coding

J-Code available

J-Code Available For Use: J2267

Submit your Omvoh claims for reimbursement: (including infusion administration costs)

  • Obtain your patient’s Explanation of Benefits (EOB)
  • Fill out CMS 1450/1500/UB04
  • Submit both forms via the Paysign Portal
  • If the claim is approved, funds will be disbursed, on behalf of the patient, to Healthcare Provider/Infusion center via preferred payment method (check or EFT)

Ordering, Billing, and Coding Guide

Download Guide Download

Medical Claims Portal User Guide for HCP Offices

Download Guide Download
hypothetical doctor standing holding a tablet

Prescribing in your Electronic Health Record System

Detailed instructions for accurate prescribing of Omvoh

ADD OMVOH TO EPIC SMARTSETS® Right
ADD OMVOH TO gGASTRO MACROS® Right
EPIC ePrescription (eRx) Instructions Right
gGastro ePrescription (eRx) Instructions Right
hypothetical doctor standing holding a tablet

Prescribing in your Electronic Health Record System

Detailed instructions for accurate prescribing of Omvoh

ADD OMVOH TO EPIC SMARTSETS® Right
ADD OMVOH TO gGASTRO MACROS® Right
EPIC ePrescription (eRx) Instructions Right
gGastro ePrescription (eRx) Instructions Right

FOR ELIGIBLE, COMMERCIALLY INSURED PATIENTS

Help your patients save on Omvoh: Patients can now save on infusion administration costs

$5 per treatment. If you have commercial insurance that covers Omvoh, you may be eligible to pay as little as $5 per treatment. $0 per treatment. If you have commerical insurance that does not cover Omvoh, you may be eligible to pay as little as $0 per treatment.

*Governmental beneficiaries excluded; terms and conditions apply.

Treatment is defined as one infusion or one 28-day supply of injections.

By enrolling in the Omvoh Savings Card Program (“Program”) and using the Omvoh Savings Card (“Card”), you attest that you meet the eligibility criteria, agree to, and will comply with the terms and conditions described below:

Eligibility:

  1. You have been prescribed Omvoh® (mirikizumab-mrkz) for an approved use consistent with FDA approved product labeling;
  2. You are enrolled in a commercial drug insurance plan;
  3. You are not enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state prescription drug assistance program;
  4. You are a resident of the United States or Puerto Rico; and
  5. You are 18 years of age or older.

Program savings for Omvoh infusions

For patients with commercial drug insurance with coverage for Omvoh: You must (a) have coverage for Omvoh through your commercial drug insurance but your insurance does not cover the full cost (i.e., you have a co-pay or coinsurance obligation) and (b) have a prescription for an approved use consistent with FDA-approved product labeling to pay as little as $5 for each infusion. The Program will cover your co-pay or coinsurance for Omvoh, less $5, up to the maximum monthly, annual, and lifetime limits outlined below. After the monthly and/or annual maximum savings are reached, you will be responsible for paying any remaining monthly/annual out-of-pocket costs. Card may be used for a maximum of up to 3 infusions over the lifetime of the Program. Program may provide support for infusions with a date of service that falls within 120 days prior to the date the enrollment form is received by the Program. Participation in the Program requires a valid patient HIPAA authorization upon enrollment into the Program. Subject to Lilly USA, LLC’s (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason, savings may continue until 12/31/2029 or for up to 36 months whichever comes first, provided you continue to meet the Program’s terms and conditions, and you first utilize the Program savings no later than 12/31/2026.

For patients with commercial drug insurance without coverage for Omvoh: You must (a) have commercial drug insurance without coverage for Omvoh, (b) have a prescription for an approved use consistent with FDA-approved product labeling, and (c) be enrolled in the Program on or before the date of the infusion to pay as little as $0 for each infusion. Card may be used for a maximum of up to 3 infusions over the lifetime of the Program. Program savings are subject to maximum monthly, annual, and lifetime limits, outlined below. After the monthly and/or annual maximum savings are reached, you will be responsible for paying any remaining monthly/annual out-of-pocket costs. To receive Program savings, your healthcare provider must submit a prior authorization (PA) request to your insurance provider before initiating treatment with Omvoh and provide the results of the PA demonstrating your insurance provider has denied coverage for non-administrative reasons to Lilly Support ServicesTM for Omvoh. Participation in the Program requires a valid patient HIPAA authorization to remain in the Program. Subject to Lilly’s right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason, savings may continue until 12/31/2029 or for up to 36 months whichever comes first, provided you continue to meet the Program’s terms and conditions, and you first utilize the Program savings no later than 12/31/2026.

Program savings for Omvoh infusion administration costs

You must (a) have commercial drug insurance but your insurance does not cover the full cost of the infusion administration (i.e., you have a co-pay) and (b) have a prescription for an approved use consistent with product labeling to receive Program savings on your infusion administration costs. Program savings are limited to up to $500 per infusion, subject to a maximum of 3 infusions over the lifetime of the Program and a separate maximum combined (infusion, infusion administration, and injection) annual savings of $10,600.00 for each calendar year. Card savings for infusion administration costs are not valid in Massachusetts, Minnesota or Rhode Island. Participation in the Program requires a valid patient HIPAA authorization upon enrollment into the Program. Subject to Lilly’s right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason, savings may continue until 12/31/2029 or for up to 36 months whichever comes first, provided you continue to meet the Program’s terms and conditions, and you first utilize the Program savings no later than 12/31/2026.

How to receive program savings for Omvoh infusions and infusion administration costs

To receive Program savings for your Omvoh infusions and/or infusion administration costs, your healthcare provider must submit a claim(s) for coverage to your medical insurance provider. If your medical insurance provider does not cover the full cost of the claim(s), you or your healthcare provider must submit a claim(s) for reimbursement, subject to the maximum reimbursement outlined herein as set forth in the instructions below.

HEALTH CARE PROVIDER SUBMISSION INSTRUCTIONS: If you have commercial drug insurance with coverage for Omvoh infusions but your insurance does not cover the full cost of the claim(s) for infusion and/or infusion administration costs, your healthcare provider must submit an Explanation of benefit (EOB) form(s) and a CMS 1450 or 1500 form to https://copayportal.paysign.com/4114419505/login within 180 days of the infusion date(s) of Omvoh. The submitted form(s) must include the name of the insurer and plan and demonstrate that Omvoh was the medication administered. If you have commercial drug insurance that does not cover Omvoh infusions, your healthcare provider must submit a PA request for Omvoh infusions to your insurance provider before initiating treatment with Omvoh and provide the results of the PA demonstrating that your insurance provider has denied coverage for non-administrative reasons to Lilly Support ServicesTM for Omvoh. You understand and agree that Lilly will make a payment of your Program savings on your behalf to your healthcare provider for reimbursable amounts that you have not already paid out-of-pocket.

PATIENT SUBMISSION INSTRUCTIONS: You must submit all required information within 180 days of the infusion date through the Program’s online patient rebate portal https://prr.paysign.com/ or by mailing a completed claim form to Paysign P.O. Box 530492 Henderson, NV 89053 Attn: Claims Processing Department. For a copy of the claim form, please call Paysign at 1-844-320-9707. Required information that must be submitted in order to receive Program savings includes your name, date of birth, address, a copy of your primary insurance card, your original activated Omvoh Savings Card information, and a copy of your Explanation of Benefits (EOB) for each claim. You understand and agree that Lilly will make a payment of your Program savings on your behalf to your healthcare provider for reimbursable amounts that you have not already paid out-of-pocket. If you have already paid for your Omvoh infusions and/or infusion administration costs, then you will also need to submit proof of payment(s) in addition to the information outlined previously in order to be eligible for reimbursement for reimbursable amounts you have paid out-of-pocket for Omvoh infusions and/or administration costs.

Program savings for Omvoh injections

For patients with commercial drug insurance with coverage for Omvoh: You must have commercial drug insurance that covers Omvoh and a prescription consistent with FDA-approved product labeling to pay as little as $5 per month for Omvoh injections. Month is defined as 28-days and up to 1 fill. Program savings are subject to maximum monthly, annual, and lifetime limits, outlined below. Card may be used for a maximum of up to 14 prescription fills of the injection per calendar year. Card may be used for a maximum of up to 14 prescription fills of the injection per calendar year. Participation in the Program requires a valid patient HIPAA authorization upon enrollment in the Program. Subject to Lilly USA, LLC’s (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason, savings may continue until 12/31/2029 or for up to 36 months whichever comes first, provided you continue to meet the Program’s terms and conditions, and you first utilize the Program savings no later than 12/31/2026.

For patients with commercial drug insurance without coverage for Omvoh: You must have commercial drug insurance without coverage for Omvoh and a prescription consistent with FDA-approved product labeling to pay as little as $0 per month for Omvoh injections. Month is defined as 28 days and up to 1 fill. Program savings are subject to maximum monthly, annual, and lifetime limits, outlined below. Card may be used for a maximum of up to 14 prescription fills of the injection per calendar year. Participation in the Program requires a valid patient HIPAA authorization to remain in the Program. To receive Program savings, your healthcare provider must submit a prior authorization (PA) request for Omvoh to your insurance provider prior to your 1st fill of Omvoh and provide the results of the PA demonstrating your insurance provider has denied coverage for non-administrative reasons to Lilly Support Services™ for Omvoh. To continue receiving Program savings, your healthcare provider must submit an appeal of the denial of coverage to your insurance provider prior to your 5th fill and provide the results of the appeal demonstrating your provider has denied coverage for non-administrative reasons to Lilly Support Services™ for Omvoh. To remain eligible for the Program, a new PA, appeal, or medical exception must be submitted prior to the 13th fill and as required by Lilly at its sole discretion. Subject to Lilly’s right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason, savings may continue until 12/31/2029 or for up to 36 months whichever comes first, provided you continue to meet the Program’s terms and conditions, and you first utilize the Program benefits no later than 12/31/2026.

Monthly, annual, and lifetime maximum savings for infusions and injections

For patients with commercial drug insurance with coverage for Omvoh: Program savings for claims covered under the medical and/or pharmacy portion of your medical insurance for Omvoh are limited to up to 3 infusions over the lifetime of the Program and up to 14 injection fills per calendar year, subject to a combined (injection and infusion) maximum monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and a separate maximum combined (injection, infusion, and infusion administration costs) annual savings of $10,600 for each calendar year. Except where prohibited by applicable state law, Card monthly and annual savings are reduced if Lilly identifies that you are enrolled in a plan or program, sometimes called a maximizer plan, that adjusts your cost sharing amount to be equal to or include some portion of the savings provided by the Card and attempts to prevent the savings from this Card from being applied to your out-of-pocket costs, including but not limited to copayments, coinsurances, and deductibles (“Maximizer”). If the Program identifies you are enrolled in a Maximizer, Card savings are reduced to a maximum monthly savings of up to $25 and a separate maximum annual savings of up to $350 per calendar year. If you have reason to believe that the Program erroneously identified enrollment in a Maximizer, please call the Omvoh Savings Card Program at 1-800-LillyRx (1-800-545-5979). Monthly and annual maximums are set at Lilly’s absolute discretion and may be changed by Lilly with or without notice.

For patients with commercial drug insurance without coverage for Omvoh: Program savings for claims not covered under the medical and/or pharmacy portion of your medical insurance are limited to up to 3 infusions over the lifetime of the Program and up to 14 injection fills per calendar year, subject to a combined (injection and infusion) maximum monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and a separate annual maximum savings. Monthly and annual maximums are set at Lilly’s absolute discretion and may be changed by Lilly with or without notice.

Additional Program Terms and Conditions

If you have an insurance plan that is participating in an alternate funding program (“AFP”) that requires you to apply to the Omvoh Savings Card Program or otherwise pursue specialty drug prescription coverage through an alternate funding vendor as a condition of, requirement for, or prerequisite to coverage of Omvoh, you are not eligible for and are prohibited from using the Omvoh Savings Card Program. AFPs include programs where coverage, reimbursement, or patient out of pocket costs for a product in some way vary based on the availability of a manufacturer co-pay program. AFPs may modify, delay, deny, restrict, or withhold insurance benefits or coverage from patients, or exclude Lilly products from coverage contingent upon a member’s use of Omvoh Savings Card Program. You agree to inform Omvoh Savings Card Program if you are or become a member of such an alternate funding program. You are responsible for any applicable taxes, fees, and any amount that exceeds the monthly or annual maximum savings. Monthly and annual maximum savings are set at Lilly’s sole and absolute discretion and may be changed by Lilly with or without notice at any time for any reason. At its sole discretion and with or without notice, Lilly may reduce, eliminate, or otherwise modify the Card savings for any reason, including but not limited to if your commercial drug insurance plan imposes additional requirements which limits or prevents you from receiving coverage for Omvoh, only allows partial coverage for Omvoh, removes coverage for Omvoh and requires you to utilize the Card, does not provide a material level of financial assistance for the cost of Omvoh, or does not apply Card payments to satisfy your co-payment, deductible, or coinsurance for Omvoh.
Program savings are limited to the co-pay or coinsurance costs for Omvoh infusions and infusion administration costs only, subject to a monthly and annual maximum savings, outlined above. The Program will not cover, and shall not be applied toward, the cost of any other dosing procedure, any other healthcare provider service or supply charges or other treatment costs, or any costs associated with a hospital stay. Program will only be accepted at participating pharmacies. Patients with commercial drug insurance without coverage for Omvoh infusion must use Lilly’s designated pharmacy vendor to obtain Program savings. Card savings are not valid for: Massachusetts residents if an AB-rated generic equivalent is available; California residents if an FDA-approved therapeutic equivalent is available. You must meet the Card eligibility criteria, terms and conditions every time you use the Card. If at any time you begin receiving drug coverage under any state, federal, or government funded healthcare program, you understand that you will no longer be eligible for the Omvoh Savings Card and agree to call Lilly Support Services™ for Omvoh at 1-800-LillyRx (1-800-545-5979) to stop participation. Card activation is required. You may not seek reimbursement from your health insurance, any third party, or any health savings, flexible spending, or other healthcare reimbursement accounts, for any amount of the savings received through the Card. By utilizing the Card, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you will notify your Insurance Carrier of your redemption of the Card. Card savings cannot be combined or utilized with any other program, discount, discount card, cash discount card, coupon, incentive, or similar offer involving Omvoh. You agree that this Card savings is intended solely for the benefit of you, the patient, and that the Card benefits are non-transferable. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase, or trade, or to counterfeit the Card. THIS CARD IS NOT INSURANCE. Lilly has the sole right to interpret and apply Card eligibility criteria, and terms and conditions. Card eligibility, and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. Lilly’s sole discretion to terminate, rescind, revoke, or amend Card eligibility and/or Card terms and conditions includes the right to terminate any individual Card if Lilly determines, in its sole discretion, that a patient does not satisfy the Card’s eligibility criteria or is using or has attempted to use the Card inconsistently with these terms and conditions. Eligibility criteria, and terms and conditions for the Omvoh Savings Card Program may change from time to time; the most current version can be found at https://www.omvoh.lilly.com/savings-support . You may be required to obtain a new Card, including if any Card terms and conditions have been terminated, rescinded, revoked, or amended by Lilly. Card void where prohibited by law. Subject to Lilly USA, LLC’s (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason, savings may continue until 12/31/2029 or for up to 36 months whichever comes first, provided you continue to meet the Program’s terms and conditions and you first utilize the Program benefits no later than 12/31/2026.

IMPORTANT SAFETY INFORMATION for Omvoh (mirikizumab-mrkz)

Warning:

CONTRAINDICATIONS - Omvoh is contraindicated in patients with a history of serious hypersensitivity reaction to mirikizumab-mrkz or any of the excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylaxis during intravenous infusion, have been reported with Omvoh administration. Infusion-related hypersensitivity reactions, including mucocutaneous erythema and pruritus, were reported during induction. If a severe hypersensitivity reaction occurs, discontinue Omvoh immediately and initiate appropriate treatment.

Infections

Omvoh may increase the risk of infection. Do not initiate treatment with Omvoh in patients with a clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing Omvoh. Instruct patients to seek medical advice if signs or symptoms of clinically important acute or chronic infection occur. If a serious infection develops or an infection is not responding to standard therapy, monitor the patient closely and do not administer Omvoh until the infection resolves.

Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Omvoh. Do not administer Omvoh to patients with active TB infection. Initiate treatment of latent TB prior to administering Omvoh. Consider anti-TB therapy prior to initiation of Omvoh in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after Omvoh treatment. In clinical trials, subjects were excluded if they had evidence of active TB, a history of active TB, or were diagnosed with latent TB at screening.

Hepatotoxicity

Drug-induced liver injury in conjunction with pruritus was reported in a clinical trial subject following a longer than recommended induction regimen. Omvoh was discontinued. Liver test abnormalities eventually returned to baseline. Evaluate liver enzymes and bilirubin at baseline and for at least 24 weeks of treatment. Monitor thereafter according to routine patient management. Consider other treatment options in patients with evidence of liver cirrhosis. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury. Interrupt treatment if drug-induced liver injury is suspected, until this diagnosis is excluded. Instruct patients to seek immediate medical attention if they experience symptoms suggestive of hepatic dysfunction.

Immunizations

Avoid use of live vaccines in patients treated with Omvoh. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating therapy, complete all age-appropriate vaccinations according to current immunization guidelines. No data are available on the response to live or non-live vaccines in patients treated with Omvoh.

ADVERSE REACTIONS

Most common adverse reactions associated with Omvoh (≥2% of subjects and at a higher frequency than placebo) in ulcerative colitis treatment are upper respiratory tract infections and arthralgia during the induction study (UC-1), and upper respiratory tract infections, injection site reactions, arthralgia, rash, headache, and herpes viral infection during the maintenance study (UC-2).

Most common adverse reactions associated with Omvoh in the Crohn’s disease study (CD-1) (≥5% of subjects and at a higher frequency than placebo) are upper respiratory tract infections, injection site reactions, headache, arthralgia, and elevated liver tests.

Omvoh injection is available as a 300mg/15 mL solution in a single-dose vial for intravenous infusion, and as a 100 mg/mL solution or a 200 mg/2 mL solution in a single dose prefilled pen or prefilled syringe for subcutaneous injection. Refer to the Prescribing Information for dosing information.

MR HCP ISI CD APP

Please see Prescribing Information and Medication Guide for Omvoh. Please see Instructions for Use included with the device.

INDICATIONS

Ulcerative Colitis
Omvoh is an interleukin-23 antagonist indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults.

Crohn's Disease
Omvoh is an interleukin-23 antagonist indicated for the treatment of moderately to severely active Crohn's disease (CD) in adults.

  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

To speak to a customer specialist:
Call 1-800-LillyRx
(1-800-545-5979)

This site is intended for US healthcare providers.

Omvoh® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Lilly Support Services™ and Companion in Care™ are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. Other product/company names mentioned herein are the trademarks of their respective owners.

CMAT-00876 11/2025 ©Lilly USA, LLC 2025. All rights reserved .

Your Privacy Choices

Cookie Settings

Terms of Use Privacy Statement Consumer Health Privacy Notice Accessibility Statement Sitemap
Eli Lilly Logo